Consider the Bisphosphonate Dose

Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5‐Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open‐Label Extension of a Randomized Controlled Trial

(2021) Andrew Grey et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance

(2017) Ashley A. Lloyd et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reference intervals for serum concentrations of three bone turnover markers for men and women

(2013) J. Michelsen et al.   BONE

Incidence of atypical nontraumatic diaphyseal fractures of the femur

(2012) Richard M Dell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization

(2011) Yohann Bala et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures

(2011) Eve Donnelly et al.   JOURNAL OF BONE AND MINERAL RESEARCH